Resumen de Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patientss: a retrospective analysis
T. Korkmaz, S. Seber, U. Kefeli, E. Sari, M. Canhoroz, Basak Oven Ustaalioglu, Mahmut Gumus, E. Yildirim, N. Yasar, D. Aydin, O. Balvan, N. Sener, S. Yuksel, A. Mert, O. Polat, F. Yumuk, Ozkan Kanat, N. S. Turhal
Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment.
Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers.
Results Median age of group was 58. 82 % had an ECOG PS of 0¿1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate.
Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
